Arog Pharmaceuticals

Company Description

We are a late-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing crenolanib in indications with high unmet need. Crenolanib is an orally administered, highly potent and selective, mutation-resistant pan-FLT3 inhibitor. To date, crenolanib has been evaluated in over 400 patients across 19 completed or ongoing clinical trials. Our vision is to prolong the lives of cancer patients by advancing crenolanib in combination with standard of care chemotherapies as well as emerging therapies that offer the potential for synergistic treatment effects. In certain diseases which currently have no approved targeted treatments, crenolanib is being evaluated as monotherapy

Company Overview

NameArog Pharmaceuticals
SectorPharma

IPO Data

Date1.02.2019
Company SymbolAROG
Stock MarketNASDAQ (NASDAQ)
Popular Investor - EN
E-NEWSLETTER SUBSCRIPTION
Subscribe to our e-mail list to be notified of updates and recent announcements on our website.
FOLLOW US
Don't forget to follow us on social media